AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25211695 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of administration with memory descriptions before well-being scales
Number of subjects: 0
Study 25211695 — intervention group
Group type: COMPARATOR
Intervention: Order of administration with well-being scales before memory descriptions
Number of subjects: 0
Study 23594227 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0916 (6 mg once daily for 14 days)
Number of subjects: 96
Study 23594227 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0916 (0.4-100 mg single doses)
Number of subjects: 96
Study 23594227 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0916 (0.2-225 mg followed by daily doses of 0.2-100 mg for 13 days)
Number of subjects: 96
Study 23594227 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0916
Number of subjects: 96
Study 21357934 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 50
Study 21357934 — intervention group
Group type: COMPARATOR
Intervention: Continuous peritoneal dialysis (CPD)
Number of subjects: 50
Study 19597267 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented strength training
Number of subjects: 10
Study 19597267 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 10
Study 17785709 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week yoga intervention (n = 84)
Number of subjects: 128
Study 17785709 — intervention group
Group type: COMPARATOR
Intervention: 12-week waitlist control group (n = 44)
Number of subjects: 128
Study 15131466 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV-4 at 1 microg
Number of subjects: 90
Study 15131466 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV-4 at 4 microg
Number of subjects: 90
Study 15131466 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV-4 at 10 microg
Number of subjects: 90
Study 15131466 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed meningococcal polysaccharide vaccine (A, C, Y, W-135) at 15 to 18 months
Number of subjects: 90
Study 11237270 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (2-week administration)
Number of subjects: 81
Study 11237270 — intervention group
Group type: COMPARATOR
Intervention: Control (no etidronate)
Number of subjects: 81
Study 9514486 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismus at 3 months
Number of subjects: 3030
Study 9514486 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismus at 12 months
Number of subjects: 3030
Study 9514486 — intervention group
Group type: EXPERIMENTAL
Intervention: Total prevalence of strabismus in the first year of life
Number of subjects: 3030
Study 9514486 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinopathy of prematurity
Number of subjects: 3030
Study 9514486 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of strabismus at 3 months
Number of subjects: 3030
Study 9514486 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisometropia, abnormal fixation, and unfavorable retinal structure
Number of subjects: 3030
Study 7802303 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA: atropine, halothane, and nitrous oxide)
Number of subjects: 18
Study 7802303 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA: hyperbaric tetracaine)
Number of subjects: 18
Study 7802303 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 18
Study 7802303 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 18
Study 7802303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 2277738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (0.5 mg b.i.d.)
Number of subjects: 23
Study 2277738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 37861 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 142
Study 37861 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 142
Study 37861 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam and Diazepam
Number of subjects: 142
Study 30372576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylindrical attachment (LA)
Number of subjects: 0
Study 30372576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachment (RA)
Number of subjects: 0
Study 30372576 — intervention group
Group type: COMPARATOR
Intervention: Crossover phase (both systems)
Number of subjects: 0
Study 27815605 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide serum markers
Number of subjects: 45
Study 27815605 — intervention group
Group type: EXPERIMENTAL
Intervention: Two peptides (from apolipoprotein M and apolipoprotein C-IV)
Number of subjects: 45
Study 27815605 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor activator, complement factor H, ceruloplasmin, and age
Number of subjects: 45
Study 25771023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐directional text messaging
Number of subjects: 121
Study 25771023 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR + reminders
Number of subjects: 121
Study 25771023 — intervention group
Group type: COMPARATOR
Intervention: EMR‐only
Number of subjects: 121
Study 23432146 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 or 40 mg once daily for 4 weeks
Number of subjects: 1388
Study 23432146 — intervention group
Group type: COMPARATOR
Intervention: Current therapy (control)
Number of subjects: 1388
Study 21310833 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g Acetyl-L-carnitine (ALC) twice a day for 90 days
Number of subjects: 121
Study 21310833 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice a day for 90 days
Number of subjects: 121
Study 19049504 — intervention group
Group type: EXPERIMENTAL
Intervention: Addenbrooke's Cognitive Examination (ACE)
Number of subjects: 44
Study 19049504 — intervention group
Group type: EXPERIMENTAL
Intervention: Scales for Outcomes of Parkinson's disease‐Cognition (SCOPA‐COG)
Number of subjects: 44
Study 19049504 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐mental state examination (MMSE)
Number of subjects: 44
Study 16696839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening test under forced right attention condition
Number of subjects: 50
Study 16696839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening test under forced left attention condition
Number of subjects: 50
Study 16696839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening test under non‐forced attention condition
Number of subjects: 50
Study 16696839 — intervention group
Group type: COMPARATOR
Intervention: Dichotic listening test
Number of subjects: 50
Study 16696839 — intervention group
Group type: EXPERIMENTAL
Intervention: General cognitive functioning
Number of subjects: 50
Study 15351417 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative closed-suction drain (Group B)
Number of subjects: 78
Study 15351417 — intervention group
Group type: COMPARATOR
Intervention: No post-operative closed-suction drain (Group A)
Number of subjects: 78
Study 15351417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 78
Study 11323328 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil/isoflurane/propofol
Number of subjects: 304
Study 11323328 — intervention group
Group type: COMPARATOR
Intervention: fentanyl/isoflurane/propofol
Number of subjects: 304
Study 9153367 — intervention group
Group type: EXPERIMENTAL
Intervention: p55‐IgG, 0.083 mg/kg
Number of subjects: 498
Study 9153367 — intervention group
Group type: EXPERIMENTAL
Intervention: p55‐IgG, 0.042 mg/kg
Number of subjects: 498
Study 9153367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 9153367 — intervention group
Group type: EXPERIMENTAL
Intervention: p55‐IgG (both doses)
Number of subjects: 498
Study 8162628 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg isosorbide dinitrate (ISDN) treatment for 4 weeks
Number of subjects: 14
Study 8162628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glyceryl trinitrate (GTN) before ISDN treatment
Number of subjects: 14
Study 8162628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glyceryl trinitrate (GTN) after ISDN treatment
Number of subjects: 14
Study 8162628 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 4 weeks
Number of subjects: 14
Study 3074604 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 0
Study 3074604 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 0
Study 31853557 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg LSD
Number of subjects: 48
Study 31853557 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg LSD
Number of subjects: 48
Study 31853557 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg LSD
Number of subjects: 48
Study 31853557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29502856 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpable tumors
Number of subjects: 1576
Study 29502856 — intervention group
Group type: COMPARATOR
Intervention: Nonpalpable tumors
Number of subjects: 1576
Study 28746179 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of NBP soft capsules orally, 15 minutes before each meal, 3 times daily for 21 days
Number of subjects: 304
Study 28746179 — intervention group
Group type: COMPARATOR
Intervention: 200 mg of placebo soft capsules orally, 15 minutes before each meal, 3 times daily for 21 days
Number of subjects: 304
Study 26275714 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 169
Study 26275714 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 169
Study 23039152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 109
Study 23039152 — intervention group
Group type: COMPARATOR
Intervention: Control (usual therapy)
Number of subjects: 109
Study 20347364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass ratio (FMR) evaluated by dual-energy X-ray absorptiometry (DXA)
Number of subjects: 221
Study 18090507 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10‐20 mg/day)
Number of subjects: 51
Study 18090507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16827695 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional dietary natural mineral water uptake
Number of subjects: 80
Study 16827695 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 80
Study 12810742 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgun purchase for self
Number of subjects: 120
Study 12810742 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgun purchase as a gift for a girl/boyfriend
Number of subjects: 120
Study 12810742 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgun purchase for a girl/boyfriend 'because s/he needs it'
Number of subjects: 120
Study 12810742 — intervention group
Group type: COMPARATOR
Intervention: Willingness to sell by region
Number of subjects: 120
Study 12810742 — intervention group
Group type: COMPARATOR
Intervention: Illegal sale condition (need)
Number of subjects: 120
Study 10925183 — intervention group
Group type: EXPERIMENTAL
Intervention: Apligraf(R) (Graftskin) applied over meshed split thickness autografts
Number of subjects: 38
Study 10925183 — intervention group
Group type: EXPERIMENTAL
Intervention: Apligraf(R) (Graftskin)
Number of subjects: 38
Study 10925183 — intervention group
Group type: COMPARATOR
Intervention: Control (meshed autograft covered with meshed allograft or not covered by a biologic dressing)
Number of subjects: 38
Study 8645027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (T group)
Number of subjects: 98
Study 8645027 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 98
Study 1597847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg three times daily for four weeks
Number of subjects: 7
Study 1597847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6089237 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS - 80 Hz
Number of subjects: 42
Study 6089237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency TENS - 2 Hz
Number of subjects: 42
Study 6089237 — intervention group
Group type: COMPARATOR
Intervention: Control group - TENS without batteries
Number of subjects: 42
Study 31774112 — intervention group
Group type: COMPARATOR
Intervention: BTLA rs1982809 SNP (AA genotype)
Number of subjects: 1236
Study 31774112 — intervention group
Group type: COMPARATOR
Intervention: TAAG haplotype (BTLA rs16859629, rs1982809, rs2171513, rs3112270)
Number of subjects: 1236
Study 30414369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (calcium channel blockers plus oxygen‐ozone treatment)
Number of subjects: 50
Study 30414369 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcium channel blockers only)
Number of subjects: 50
Study 30414369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 50
Study 30414369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 27553267 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (LH anodal/RH cathodal)
Number of subjects: 32
Study 27553267 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (RH anodal/LH cathodal)
Number of subjects: 32
Study 27553267 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study 24556445 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (ECV)
Number of subjects: 3940
Study 24556445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion (PCV)
Number of subjects: 3940
Study 24556445 — intervention group
Group type: COMPARATOR
Intervention: No cardioversion during admission
Number of subjects: 3940
Study 24556445 — intervention group
Group type: EXPERIMENTAL
Intervention: ECV with antiarrhythmic drugs (mostly amiodarone)
Number of subjects: 3940
Study 24556445 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV with class Ic antiarrhythmic drugs
Number of subjects: 3940
Study 24556445 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic antiarrhythmic drugs, beta-blockers, or inhibitors of the renin-angiotensin system
Number of subjects: 3940
Study 24556445 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hospital stay for ECV
Number of subjects: 3940
Study 24556445 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hospital stay for PCV
Number of subjects: 3940
Study 24556445 — intervention group
Group type: EXPERIMENTAL
Intervention: CV-related complications
Number of subjects: 3940
Study 22098133 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus L. gasseri-containing yogurt (112 g, twice daily for 4 weeks)
Number of subjects: 229
Study 22098133 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid)
Number of subjects: 229
Study 22098133 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus L. gasseri-containing yogurt
Number of subjects: 229
Study 22098133 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 229
Study 19287288 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 86
Study 19287288 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab
Number of subjects: 86
Study 17081222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-appliance therapy
Number of subjects: 48
Study 17081222 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 48
Study 17081222 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched males without sexual problems)
Number of subjects: 48
Study 14985668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phenytoin
Number of subjects: 0
Study 14985668 — intervention group
Group type: COMPARATOR
Intervention: Intravenous phenytoin
Number of subjects: 0
Study 14985668 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fosphenytoin
Number of subjects: 0
Study 14985668 — intervention group
Group type: COMPARATOR
Intervention: Oral phenytoin vs Intravenous phenytoin
Number of subjects: 0
Study 14985668 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fosphenytoin vs Intravenous phenytoin
Number of subjects: 0
Study 11598356 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezo-assisted ICSI
Number of subjects: 204
Study 11598356 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICSI
Number of subjects: 204
Study 10916570 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISCA 3.0 software for twin pregnancy
Number of subjects: 889
Study 10916570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulm Index for fetal trisomy 21 risk calculation
Number of subjects: 889
Study 10916570 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP determination for fetal open NTD in twin pregnancy
Number of subjects: 889
Study 10916570 — intervention group
Group type: COMPARATOR
Intervention: PRISCA 3.0 software for singleton pregnancy
Number of subjects: 889
Study 10916570 — intervention group
Group type: COMPARATOR
Intervention: AFP determination for fetal open NTD in singleton pregnancy
Number of subjects: 889
Study 8052154 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fenfluramine 15 mg twice daily
Number of subjects: 17
Study 8052154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3132220 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial immunodiffusion
Number of subjects: 1328
Study 3132220 — intervention group
Group type: COMPARATOR
Intervention: Hemoccult II with rehydration
Number of subjects: 1328
Study 3132220 — intervention group
Group type: COMPARATOR
Intervention: Hemoccult II without rehydration
Number of subjects: 1328
Study 3132220 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological technique
Number of subjects: 1328
Study 29172605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 62
Study 29172605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 62
Study 29172605 — intervention group
Group type: COMPARATOR
Intervention: Waiting-List Control (WLC)
Number of subjects: 62
Study 26634956 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BBUP) 150-450 µg every 12 hours
Number of subjects: 749
Study 26634956 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BBUP)
Number of subjects: 749
Study 26634956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study 24985779 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 1952
Study 24985779 — intervention group
Group type: COMPARATOR
Intervention: Standard ART
Number of subjects: 1952
Study 21931012 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser treatment (EVLT)
Number of subjects: 400
Study 21931012 — intervention group
Group type: COMPARATOR
Intervention: High ligation and stripping (HLS)
Number of subjects: 400
Study 21931012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 400
Study 20873270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition optimization as part of maintenance therapy
Number of subjects: 0
Study 20873270 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher motor activity
Number of subjects: 0
Study 18390020 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN+)
Number of subjects: 21
Study 18390020 — intervention group
Group type: COMPARATOR
Intervention: No Patient Navigation (PN-)
Number of subjects: 21
Study 16815467 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.25 mg/kg)
Number of subjects: 60
Study 16815467 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa (100/25 mg)
Number of subjects: 60
Study 16815467 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 12707152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 2074
Study 12707152 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 2074
Study 11056999 — intervention group
Group type: EXPERIMENTAL
Intervention: Two levels of stimulus-response compatibility
Number of subjects: 104
Study 11056999 — intervention group
Group type: EXPERIMENTAL
Intervention: Two levels of stimulus discriminability
Number of subjects: 104
Study 11056999 — intervention group
Group type: EXPERIMENTAL
Intervention: Two levels of response repertoire
Number of subjects: 104
Study 8882175 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed nets (PIBs)
Number of subjects: 1398
Study 8882175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bed nets)
Number of subjects: 1398
Study 1448534 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheets (Spenco) worn continuously for 12 hours for 12 weeks
Number of subjects: 14
Study 1448534 — intervention group
Group type: COMPARATOR
Intervention: Kenalog injection (40 mg/ml x 1 cc mixed with 1 cc of 1% Xylocaine with epinephrine)
Number of subjects: 14
Study 2864962 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (30 g/day)
Number of subjects: 19
Study 2864962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30809083 — intervention group
Group type: EXPERIMENTAL
Intervention: High nutrient drink (500 kcal)
Number of subjects: 20
Study 30809083 — intervention group
Group type: COMPARATOR
Intervention: Low nutrient drink (250 kcal)
Number of subjects: 20
Study 29056072 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item ShortMAC
Number of subjects: 206
Study 29056072 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional 24-item WOMAC
Number of subjects: 206
Study 29056072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain subscale of ShortMAC
Number of subjects: 206
Study 29056072 — intervention group
Group type: EXPERIMENTAL
Intervention: Function subscale of ShortMAC
Number of subjects: 206
Study 29056072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain subscale of Traditional WOMAC
Number of subjects: 206
Study 29056072 — intervention group
Group type: EXPERIMENTAL
Intervention: Function subscale of Traditional WOMAC
Number of subjects: 206